Rohto Pharmaceutical Co Ltd (JP:4527)
:4527
Top Page
Rohto Pharmaceutical Co
(4527)
Select Model
Select Model
Rating:71Outperform
Price Target:
¥2,876.00
▲(12.34% Upside)
Action:UpgradedDate:10/29/25
Rohto Pharmaceutical's overall stock score is driven by its strong financial performance, which is the most significant factor. The technical analysis indicates a lack of strong momentum, which slightly offsets the financial strengths. The valuation is reasonable, providing a balanced outlook.
Positive Factors
High margins & revenue growth
Consistent revenue gains and high margins indicate durable demand and pricing power across Rohto’s product portfolio. Gross margin 54.88% and net margin 10.05% support long-term cash generation and reinvestment capacity, helping the company withstand competitive pressure.
Negative Factors
Product concentration risk
Concentration in OTC eye-care and personal-care products creates revenue concentration risk. Market share shifts, changing consumer preferences, or retail channel disruption could disproportionately affect sales and slow durable growth if new categories or geographies underperform.
Read all positive and negative factors
Positive Factors
Negative Factors
High margins & revenue growth
Consistent revenue gains and high margins indicate durable demand and pricing power across Rohto’s product portfolio. Gross margin 54.88% and net margin 10.05% support long-term cash generation and reinvestment capacity, helping the company withstand competitive pressure.
Read all positive factors
Rohto Pharmaceutical Co (4527) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥544.30B
Dividend Yield1.53%
Average Volume (3M)643.03K
Price to Earnings (P/E)14.0
Beta (1Y)0.49
Revenue Growth18.35%
EPS Growth31.87%
CountryJP
Employees7,259
SectorConsumer Defensive
Sector Strength42
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)47.03
Shares Outstanding236,178,310
10 Day Avg. Volume564,110
30 Day Avg. Volume643,026
Financial Highlights & Ratios
PEG Ratio43.69
Price to Book (P/B)1.96
Price to Sales (P/S)1.65
P/FCF Ratio18.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥2,980.00Price Target Upside16.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)148.12
Revenue Forecast (FY)¥338.96B
Rohto Pharmaceutical Co Business Overview & Revenue Model
Company Description
Rohto Pharmaceutical Co.,Ltd. manufactures and markets pharmaceutical products, cosmetics, and functional foods worldwide. The company provides eye care products, such as eye drops, care for contact lenses, and eye wash; and facial care products c...
How the Company Makes Money
Rohto Pharmaceutical generates revenue primarily through the sale of its consumer healthcare products, which include eye care solutions, skin care products, and OTC medications. The company has a diverse portfolio, with its eye drops being among i...
Rohto Pharmaceutical Co Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
80
Positive
Cash Flow
78
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 322.23B | 308.63B | 270.84B | 238.66B | 199.65B | 181.05B |
| Gross Profit | 179.71B | 169.46B | 154.93B | 135.13B | 114.10B | 104.96B |
| EBITDA | 53.22B | 51.61B | 48.85B | 41.34B | 35.55B | 28.61B |
| Net Income | 34.23B | 31.00B | 30.94B | 26.38B | 21.13B | 16.74B |
Balance Sheet | ||||||
| Total Assets | 428.33B | 421.88B | 346.18B | 309.68B | 274.88B | 226.15B |
| Cash, Cash Equivalents and Short-Term Investments | 75.84B | 77.16B | 89.21B | 79.95B | 72.79B | 52.96B |
| Total Debt | 48.88B | 61.23B | 12.81B | 12.88B | 21.72B | 8.49B |
| Total Liabilities | 144.18B | 150.43B | 99.14B | 94.60B | 90.88B | 69.53B |
| Stockholders Equity | 266.74B | 260.10B | 246.33B | 209.57B | 178.40B | 155.91B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 27.84B | 26.27B | 22.45B | 16.98B | 11.29B |
| Operating Cash Flow | 0.00 | 36.92B | 34.24B | 30.92B | 27.25B | 20.01B |
| Investing Cash Flow | 0.00 | -57.55B | -16.32B | -13.18B | -16.41B | -10.24B |
| Financing Cash Flow | 0.00 | 3.70B | -13.78B | -16.20B | 3.47B | -2.35B |
Rohto Pharmaceutical Co Technical Analysis
Negative
2560.00
Price Trends
2478.54
Negative
2498.30
Negative
2399.22
Negative
Market Momentum
-28.48
Negative
43.72
Neutral
55.05
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4527, the sentiment is Negative. The current price of 2560 is above the 20-day moving average (MA) of 2355.88, above the 50-day MA of 2478.54, and above the 200-day MA of 2399.22, indicating a bearish trend. The MACD of -28.48 indicates Negative momentum. The RSI at 43.72 is Neutral, neither overbought nor oversold. The STOCH value of 55.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4527.
Rohto Pharmaceutical Co Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ¥433.02B | 16.53 | 9.09% | 1.73% | 2.18% | 60.81% | |
71 Outperform | ¥544.30B | 13.97 | 12.66% | 1.53% | 18.35% | 31.87% | |
70 Outperform | ¥2.72T | 24.05 | 11.50% | 2.41% | 4.62% | 47.68% | |
69 Neutral | ¥331.52B | 19.79 | 2.72% | 2.61% | 1.37% | -5.60% | |
65 Neutral | ¥415.98B | 110.37 | 5.37% | 1.95% | -3.33% | 13.76% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
56 Neutral | ¥1.17T | -22.37 | ― | 2.11% | -1.20% | -2896.72% |
* Consumer Defensive Sector Average
JP:4527
Rohto Pharmaceutical Co
2,373.00
138.70
6.21%
JP:4452
Kao
6,022.00
-379.23
-5.92%
JP:4967
Kobayashi Pharmaceutical Co
5,693.00
12.25
0.22%
JP:4922
Kose
5,833.00
-501.54
-7.92%
JP:4912
Lion
1,609.00
-130.13
-7.48%
JP:4911
Shiseido Company,Limited
2,985.50
160.57
5.68%
Rohto Pharmaceutical Co Corporate Events
Rohto Pharmaceutical to Acquire Thailand’s THANN to Bolster Global Wellness Strategy
Jan 7, 2026
Rohto Pharmaceutical has decided, via a subsidiary, to acquire shares in Thailand-based wellness company Thann Oryza Co., Ltd. (THANN), making it a group subsidiary as part of a strategy to accelerate value creation in the well-being domain. THANN...
Rohto Pharmaceutical Acquires OBAGI Trademarks in Japan
Nov 13, 2025
Rohto Pharmaceutical Co., Ltd. has announced the acquisition of OBAGI-related trademarks in Japan from OBAGI COSMECEUTICALS LLC, a subsidiary of Waldencast plc, for USD 82.5 million. This strategic move allows Rohto to permanently secure licensing...
Rohto Pharmaceutical Revises Earnings and Dividend Forecasts Upward
Nov 13, 2025
Rohto Pharmaceutical Co., Ltd. has revised its earnings and dividend forecasts for the fiscal year ending March 31, 2026, due to stronger-than-expected performance in Japan, Asia, and the Americas. The company anticipates higher net sales and prof...
Rohto Pharmaceutical Reports Strong Financial Growth and Strategic Expansion
Nov 13, 2025
Rohto Pharmaceutical Co. reported a significant increase in its financial performance for the six months ended September 30, 2025, with net sales rising by 18.1% and profit attributable to owners of the parent increasing by 36.6% compared to the p...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.